Latest News

While we enjoy watching the progress our portfolio companies make, we appreciate this does not come easily and requires large measures of expertise, intuition, ingenuity and perseverance. This understanding increases our satisfaction in bringing you news of their accomplishments.

Use the filters above to refine results
19th December 2019

Exicure Announces Pricing of $27.5 Million Public Offering of Common Stock

19th December 2019

Median Technologies announces the signing of a € 35 million finance contract with the European Investment Bank (EIB)

19th December 2019

Venatorx Pharmaceuticals Joins the Alliance for Biosecurity

9th December 2019

Jasper Therapeutics Launches with $35 Million Series A Financing to Develop and Commercialize Innovative Conditioning Agents and Therapies to Transform Curative Hematopoietic Cell Transplants

2nd December 2019

IFM Therapeutics Announces $55.5 Million Financing to Launch and Fund New Subsidiaries and Appointment of Dr. H. Martin Seidel as Chief Executive Officer

26th November 2019

Sierra Oncology Announces Closing of $103 Million Public Offering and Changes to its Board of Directors

25th November 2019

CARB-X funds VenatoRx Pharmaceuticals to support the development of a new class of oral antibiotics to treat multi-drug-resistant gonorrhea

14th November 2019

Exicure and Allergan Enter Into Collaboration, Option and License Agreement to Discover and Develop SNA-based Treatments for Hair Loss Disorders

13th November 2019

Abingworth appoints Neil Cooper as Chief Financial Officer

8th November 2019

Sierra Oncology Announces Pricing of $103 Million Public Offering of Convertible Preferred Stock and Warrants

24th October 2019

Phathom Pharmaceuticals Announces Pricing of Initial Public Offering

16th October 2019

Adaptate Biotherapeutics formed to develop antibody-based therapies that modulate gamma delta T-cells

5th September 2019

IFM Therapeutics Announces Collaboration and Exclusive Option Agreement for cGAS/STING-Focused Subsidiary, IFM Due

5th September 2019

Avillion Appoints Dr Anders Gersel Pedersen, M.D., Ph.D. as Board Member

29th August 2019

VenatoRx Pharmaceuticals Initiates Enrollment in Phase 3 Trial of Cefepime/VNRX-5133 in Patients with Complicated Urinary Tract Infections

7th August 2019

Exicure Appoints Dr. Bali Muralidhar of Abingworth to its Board of Directors

7th August 2019

Exicure Announces Uplisting to Nasdaq and Closing of $63 Million Offering of Common Stock

7th August 2019

Glaukos and Avedro Announce Definitive Acquisition Agreement

5th August 2019

Verona Pharma Reports Positive Phase 2 Results with Dry Powder Inhaler Formulation of Ensifentrine in COPD

23rd July 2019

Chiasma Announces Positive Phase 3 Top-Line Results from CHIASMA OPTIMAL Clinical Trial of Mycapssa® for the Maintenance Treatment of Adults with Acromegaly

22nd July 2019

HHS, DoD, VenatoRx Pharmaceuticals to co-develop novel antibiotic to treat drug-resistant infections

20th June 2019

Personalis Prices Initial Public Offering of Common Stock

6th June 2019

Vertex Expands into New Disease Areas and Enhances Gene Editing Capabilities Through Expanded Collaboration with CRISPR Therapeutics and Acquisition of Exonics Therapeutics

5th June 2019

Chiasma Strengthens Leadership Team Ahead of Anticipated Commercial Availability of Mycapssa®

4th June 2019

Verona Pharma Initiates Phase 2 Clinical Trial with Metered Dose Inhaler Formulation of Ensifentrine for Maintenance Treatment of COPD

3rd June 2019

IND for NOUS-209, an ‘off-the-shelf’ Neoantigen Cancer Vaccine, Cleared by FDA to Commence Clinical Development in MSI Solid Tumors

15th May 2019

Takeda and Frazier Healthcare Partners Announce Collaboration to Launch Phathom Pharmaceuticals

2nd May 2019

Lloyd Diamond will serve as Chief Executive Officer of Pixium Vision

12th April 2019

Astex Pharmaceuticals Celebrates as Second New Cancer Drug Receives US Marketing Approval

3rd April 2019

VIZIMPRO® (dacomitinib) Receives Marketing Authorization in European Union (EU) for the First-Line Treatment of Adult Patients with EGFR-Mutated Non-Small Cell Lung Cancer

1st April 2019

Novartis to Acquire IFM Tre to Develop First-In-Class NLRP3 Antagonist Portfolio Targeting Innate Immune System

27th March 2019

Tizona Announces Initiation of Phase 1/1b Study with Novel Cancer Immunotherapy TTX-030 and First Public Presentation of Pre-Clinical Data with TTX-030 at AACR 2019

26th March 2019

Abingworth appoints Bali Muralidhar as Partner

28th February 2019

Apellis Pharmaceuticals Announces Collaboration with SFJ Pharmaceuticals® for APL-2 in Hematologic Indications

13th February 2019

Avedro Announces Pricing of Initial Public Offering

11th February 2019

IFM Therapeutics Launches New Subsidiary, IFM Due, to Advance cGAS/STING Antagonists for Serious Inflammatory and Autoimmune Diseases

4th February 2019

GenSight Biologics reports topline results at Week 48 of the RESCUE Phase III clinical trial of GS010 in subjects within six months of visual loss onset due to Leber Hereditary Optic Neuropathy (LHON)

1st February 2019

Pfizer Receives Positive CHMP Opinion for Vizimpro® (dacomitinib) for the First-line Treatment of Adult Patients with Locally Advanced Or Metastatic Non-Small Cell Lung Cancer with EGFR-Activating Mutations

30th January 2019

Beckman Coulter Life Sciences Acquires Labcyte To Expand Laboratory Automation Business

14th January 2019

Verona Pharma Reports Encouraging Top-Line Data from Three-Day Phase 2 Trial Evaluating Nebulized Ensifentrine (RPL554) on Top of Dual Bronchodilator Therapy for COPD Maintenance Treatment

8th January 2019

Pixium Vision announces its wireless PRIMA chip successfully met the interim study endpoints for dry Age-related Macular Degeneration

4th January 2019

CRISPR Therapeutics and Vertex Announce FDA Fast Track Designation for CTX001 for the Treatment of Sickle Cell Disease

3rd January 2019

Gynesonics Announces $75 Million Financing

3rd January 2019

AbbVie and Tizona Therapeutics Announce Strategic Collaboration to Develop First-in-Class Immunotherapy for Cancer Targeting CD39

3rd January 2019

Tizona Therapeutics Appoints Scott Clarke as Chief Executive Officer and Provides Update on Regulatory Milestone for its First-in-Class CD39 program in Cancer